Journal: Materials Today Bio

Article Title: Identification of a myosin 1B-binding aptamer for fluorescence imaging and targeted therapy of esophageal squamous cell carcinoma

doi: 10.1016/j.mtbio.2026.102867

Figure Lengend Snippet: Selection and identification of DNA aptamers specific to ESCC. (A) Flow cytometry assays of the binding of the selected libraries to KYSE30 and Het-1A cells. (B) Flow cytometry assays of the binding of Z1-6 aptamer candidates to KYSE30 and Het-1A cells. (C) The binding signal-to-background ratio (SBR) calculation in B. Fluorescence intensity of random ssDNA was used as the background signal. (D) Confocal imaging of KYSE30 cells incubated with FAM-labeled Z1, Z2, and Z4 aptamers. The scale bar is 50 μm. (E) Determination of dissociation constant (K d ) of Z1, Z2, and Z4 aptamers for KYSE30 cells by flow cytometry. FAM-labeled random ssDNA was used as the negative control.

Article Snippet: To investigate the Dox loading capacity, Dox was fixed at 2 μM, and various aptamer-to-Dox ratios (0, 1:20, 1:15, 1:10, 1:7.5, 1:5, 1:3, and 1:2) were prepared as above mentioned, and Dox fluorescence was examined by F-7000 fluorescence spectrometer (Hitachi, Japan).

Techniques: Selection, Flow Cytometry, Binding Assay, Fluorescence, Imaging, Incubation, Labeling, Negative Control

Journal: Materials Today Bio

Article Title: Identification of a myosin 1B-binding aptamer for fluorescence imaging and targeted therapy of esophageal squamous cell carcinoma

doi: 10.1016/j.mtbio.2026.102867

Figure Lengend Snippet: Flow cytometry assays of the binding of Z1 (blue), Z2 (orange), and Z4 (green) aptamers to different cell lines. Random ssDNA (red) was used as the control probe. Aptamers and random ssDNA were labeled with FAM group for collecting fluorescence signals.

Article Snippet: To investigate the Dox loading capacity, Dox was fixed at 2 μM, and various aptamer-to-Dox ratios (0, 1:20, 1:15, 1:10, 1:7.5, 1:5, 1:3, and 1:2) were prepared as above mentioned, and Dox fluorescence was examined by F-7000 fluorescence spectrometer (Hitachi, Japan).

Techniques: Flow Cytometry, Binding Assay, Control, Labeling, Fluorescence

Journal: Materials Today Bio

Article Title: Identification of a myosin 1B-binding aptamer for fluorescence imaging and targeted therapy of esophageal squamous cell carcinoma

doi: 10.1016/j.mtbio.2026.102867

Figure Lengend Snippet: Fluorescence imaging of ESCC tissues with Cy5-labeled aptamer probes. (A) Representative images of ESCC and adjacent tissues stained with Cy5-labeled Z2 and Z4-6 aptamer probes. Cy5-labeled random ssDNA was used as the control probe. Scale bar is 50 μm. (B) Quantitative fluorescence intensity of ESCC and adjacent tissues stained with Cy5-labeled Z2 probes. (C) Quantitative fluorescence intensity of ESCC and adjacent tissues stained with Cy5-labeled Z4-6 probes. The asterisks indicate significance, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001.

Article Snippet: To investigate the Dox loading capacity, Dox was fixed at 2 μM, and various aptamer-to-Dox ratios (0, 1:20, 1:15, 1:10, 1:7.5, 1:5, 1:3, and 1:2) were prepared as above mentioned, and Dox fluorescence was examined by F-7000 fluorescence spectrometer (Hitachi, Japan).

Techniques: Fluorescence, Imaging, Labeling, Staining, Control

Journal: Materials Today Bio

Article Title: Identification of a myosin 1B-binding aptamer for fluorescence imaging and targeted therapy of esophageal squamous cell carcinoma

doi: 10.1016/j.mtbio.2026.102867

Figure Lengend Snippet: Selective cytotoxicity of Z4-6-Dox. (A) Schematic illustration of construction of Z4-6-Dox. (B) Fluorescence spectrum of Dox incubated with various concentration of Z4-6. Dox was fixed at 2 μM. (C) Flow cytometry assays of binding of Cy5-labeled Z4-6 and Z4-6-Dox to KYSE30 cells. Confocal imaging of KYSE30 (D) and Het-1A (E) cells treated with 4 μM Dox and 0.8 μM Z4-6-Dox. Cell nuclei were stained with Hoechst33342. CCK-8 assays of KYSE30 (F) and Het-1A (G) cells treated with 0.8 μM Z4-6 and Z4-6-Dox, and 4 μM Dox. The asterisks indicate significance, ∗∗∗ P < 0.001, ns indicates no significance. (H) Calcein-AM/PI imaging of KYSE30 and Het-1A cells treated with 0.8 μM Z4-6 and Z4-6-Dox, and 4 μM Dox. The green indicates Calcein-AM-stained live cells, and the red indicates PI-stained dead cells. (I) The percentage of dead cells was calculated. Untreated cells are the controls. The asterisks indicate significance, ∗∗ P < 0.01, ∗∗∗ P < 0.001.

Article Snippet: To investigate the Dox loading capacity, Dox was fixed at 2 μM, and various aptamer-to-Dox ratios (0, 1:20, 1:15, 1:10, 1:7.5, 1:5, 1:3, and 1:2) were prepared as above mentioned, and Dox fluorescence was examined by F-7000 fluorescence spectrometer (Hitachi, Japan).

Techniques: Fluorescence, Incubation, Concentration Assay, Flow Cytometry, Binding Assay, Labeling, Imaging, Staining, CCK-8 Assay

Journal: Materials Today Bio

Article Title: Identification of a myosin 1B-binding aptamer for fluorescence imaging and targeted therapy of esophageal squamous cell carcinoma

doi: 10.1016/j.mtbio.2026.102867

Figure Lengend Snippet: In vivo fluorescence imaging with the Z4-6-Cy5 probe. Time-lapse fluorescence imaging of mice bearing KYSE30 tumors after injected with the Z4-6-Cy5 (A) and Random-Cy5 (C) probes. Fluorescence images of excised heart (1), liver (2), spleen (3), lung (4), kidney (5), tumor (6) tissues from mouse model injected with the Z4-6-Cy5 (B) and Random-Cy5 (D) probes. (E) The quantitative analysis of fluorescence intensity at tumor sites in mice treated with the Z4-6-Cy5 and Random-Cy5 probes. (F) The quantitative analysis of fluorescence intensity in excised tumors and major organs.

Article Snippet: To investigate the Dox loading capacity, Dox was fixed at 2 μM, and various aptamer-to-Dox ratios (0, 1:20, 1:15, 1:10, 1:7.5, 1:5, 1:3, and 1:2) were prepared as above mentioned, and Dox fluorescence was examined by F-7000 fluorescence spectrometer (Hitachi, Japan).

Techniques: In Vivo, Fluorescence, Imaging, Injection

Journal: ACS biomaterials science & engineering

Article Title: Sialic Acid Binding Liposome Nanoparticles for Targeted Bladder Cancer Therapy

doi: 10.1021/acsbiomaterials.5c01546

Figure Lengend Snippet: (A) H 1 NMR spectra of Chitosan-CPBA and (B) Chitosan. (C) Hydrodynamic size and (D) zeta potential of liposome (LP) and liposome-chitosan (LPC) NPs. (E) Hydrodynamic size and (F) zeta potential of liposome (LP) and liposome-chitosan-CPBA (LPCB) NPs. (G) Cumulative doxorubicin (Dox) release from Dox and R848 coloaded liposome-chitosan-CPBA (LPCBDR) and liposome-chitosan (LPCDR) NPs at different pH conditions (6.4, 7.4). (H) Cumulative R848 release from LPCBDR and LPCDR NPs at different pH conditions (6.4, 7.4). Data was presented as mean ± SEM ( n = 3 replicates).

Article Snippet: Doxorubicin hydrochloride (Dox) and resiquimod (R848) were obtained from MedChemExpress.

Techniques: Zeta Potential Analyzer

Journal: ACS biomaterials science & engineering

Article Title: Sialic Acid Binding Liposome Nanoparticles for Targeted Bladder Cancer Therapy

doi: 10.1021/acsbiomaterials.5c01546

Figure Lengend Snippet: (A) Treatment schedule for different groups of C57BL/6 mice bearing subcutaneous MB49 tumors, with intravenous administration of doxorubicin (20 μ g/mouse) and R848 (8 μ g/mouse), given three times in total. (B) Tumor growth curves of MB49 subcutaneous tumors in C57BL/6 mice across different treatment groups during treatment ( n = 5). (C) Body weight changes of mice during treatment. (D) Representative images of tumors harvested from each group on Day 21. (E) Tumor volumes and (F) tumor weights of tumors collected on Day 21. Treatment groups: PBS group, mice received 100 μ L of PBS; free Dox and R848 group (FDR), mice received a combination of 20 μ g Dox and 8 μ g R848 in 100 mL of PBS; liposome-chitosan-Dox-R848 group (LPCDR), mice received LPCDR NPs containing 20 μ g Dox and 8 μ g R848 in 100 mL of PBS; liposome-chitosan-CPBA-Dox-R848 group (LPCBDR), mice received LCBDR NPs containing the same dose of Dox and R848 in 100 μ L of PBS. * P < 0.05; ** P < 0.01; *** P < 0.001. Data was presented as mean ± SEM.

Article Snippet: Doxorubicin hydrochloride (Dox) and resiquimod (R848) were obtained from MedChemExpress.

Techniques: